skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Overview
Datamonitor Healthcare uses a patient-based approach to size the commercial potential of Alzheimer’s disease across the US, Japan, and the five major EU markets (France, Germany, Italy, Spain, and the UK) from 2012 to 2021.

Highlights
Alzheimer’s disease across the US, Japan, and five major EU markets is set to double in value over the next 10 years. The catalysts for this growth include an increasingly elderly population, earlier and improved diagnosis, and the introduction of new therapeutic classes.

Pfizer/Eisai’s Aricept, formerly the highest selling brand in the market, has been overtaken by Forest/Lundbeck/Merz’s Namenda (memantine). The two drugs are following differing growth trajectories: Namenda’s sales will continue to rise while Aricept’s revenues are severely eroded by generic competition.

The beta amyloid immunotherapy solanezumab has the potential to grow the market by $4.6bn. Datamonitor Healthcare forecasts that around 330,000 patients with mild cognitive impairment or mild to moderate Alzheimer’s disease will receive immunotherapies annually by 2021 in the US, Japan, and the five major EU markets.

Methodology
Patient-based forecasting methodology utilizing epidemiology data and primary research with 133 neurologists across the US, Japan, and five major EU markets. Pricing, dosing, and future event assumptions are added to create Datamonitor Healthcare’s forecast.

 


This is an Alzheimer’s Disease analysis update from the Datamonitor Healthcare service, which provides regular and event-senstive research for key drugs and companies, treatment trends, patient populations and strategic issues.

おすすめのニュース&レポート

;

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。